438 related articles for article (PubMed ID: 33567616)
21. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.
Xiao X; Wang W; Li Y; Yang D; Li X; Shen C; Liu Y; Ke X; Guo S; Guo Z
J Exp Clin Cancer Res; 2018 Aug; 37(1):201. PubMed ID: 30153855
[TBL] [Abstract][Full Text] [Related]
22. HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.
Wang H; Sun W; Sun M; Fu Z; Zhou C; Wang C; Zuo D; Zhou Z; Wang G; Zhang T; Xu J; Chen J; Wang Z; Yin F; Duan Z; Hornicek FJ; Cai Z; Hua Y
Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1839-1849. PubMed ID: 29524631
[TBL] [Abstract][Full Text] [Related]
23. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?
Jaffe N; Carrasco H; Raymond K; Ayala A; Eftekhari F
Cancer; 2002 Nov; 95(10):2202-10. PubMed ID: 12412175
[TBL] [Abstract][Full Text] [Related]
24. Role of autophagy in osteosarcoma.
Camuzard O; Santucci-Darmanin S; Carle GF; Pierrefite-Carle V
J Bone Oncol; 2019 Jun; 16():100235. PubMed ID: 31011524
[TBL] [Abstract][Full Text] [Related]
25. CXCR4 in human osteosarcoma malignant progression. The response of osteosarcoma cell lines to the fully human CXCR4 antibody MDX1338.
Pollino S; Palmerini E; Dozza B; Bientinesi E; Piccinni-Leopardi M; Lucarelli E; Righi A; Benassi MS; Pazzaglia L
J Bone Oncol; 2019 Aug; 17():100239. PubMed ID: 31193811
[TBL] [Abstract][Full Text] [Related]
26. Podocalyxin promotes cisplatin chemoresistance in osteosarcoma cells through phosphatidylinositide 3-kinase signaling.
Huang Z; Huang Y; He H; Ni J
Mol Med Rep; 2015 Sep; 12(3):3916-3922. PubMed ID: 26017117
[TBL] [Abstract][Full Text] [Related]
27. Engineered biomaterial delivery strategies are used to reduce cardiotoxicity in osteosarcoma.
Hou Y; Wang J; Wang J
Front Pharmacol; 2023; 14():1284406. PubMed ID: 37854721
[TBL] [Abstract][Full Text] [Related]
28. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
29. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy resistance in osteosarcoma: current challenges and future directions.
Chou AJ; Gorlick R
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1075-85. PubMed ID: 16831079
[TBL] [Abstract][Full Text] [Related]
31. Relevance of 3d culture systems to study osteosarcoma environment.
De Luca A; Raimondi L; Salamanna F; Carina V; Costa V; Bellavia D; Alessandro R; Fini M; Giavaresi G
J Exp Clin Cancer Res; 2018 Jan; 37(1):2. PubMed ID: 29304852
[TBL] [Abstract][Full Text] [Related]
32. Origin and Therapies of Osteosarcoma.
Moukengue B; Lallier M; Marchandet L; Baud'huin M; Verrecchia F; Ory B; Lamoureux F
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884563
[TBL] [Abstract][Full Text] [Related]
33. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.
Wen JF; Jiang YQ; Li C; Dai XK; Wu T; Yin WZ
Cancer Biomark; 2020; 28(2):231-246. PubMed ID: 32508321
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin Resistance in Osteosarcoma:
Fanelli M; Tavanti E; Patrizio MP; Vella S; Fernandez-Ramos A; Magagnoli F; Luppi S; Hattinger CM; Serra M
Front Oncol; 2020; 10():331. PubMed ID: 32211337
[TBL] [Abstract][Full Text] [Related]
35. Identification of potential chemoresistance genes in osteosarcoma.
Walters DK; Steinmann P; Langsam B; Schmutz S; Born W; Fuchs B
Anticancer Res; 2008; 28(2A):673-9. PubMed ID: 18507006
[TBL] [Abstract][Full Text] [Related]
36. Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
Gougelet A; Pissaloux D; Besse A; Perez J; Duc A; Dutour A; Blay JY; Alberti L
Int J Cancer; 2011 Aug; 129(3):680-90. PubMed ID: 20949564
[TBL] [Abstract][Full Text] [Related]
37. Recent Insights into Therapy Resistance in Osteosarcoma.
Prudowsky ZD; Yustein JT
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33396725
[TBL] [Abstract][Full Text] [Related]
38. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.
Meng Y; Gao R; Ma J; Zhao J; Xu E; Wang C; Zhou X
Sci Rep; 2017 Mar; 7(1):416. PubMed ID: 28341864
[TBL] [Abstract][Full Text] [Related]
40. Molecular mechanisms for tumour resistance to chemotherapy.
Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
